JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
NCT ID: NCT04721223
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
12 participants
INTERVENTIONAL
2021-04-26
2023-12-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
NCT03565003
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
NCT03518554
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
NCT04686682
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
NCT04587479
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JAB-3068+PD1 inhibitor Part1
JAB-3068+JS001 dose escalation
JAB-3068
JAB-3068 administrated orally as a tablet.
PD1 inhibitor
JS001 administrated as an intravenous(IV) infusion.
JAB-3068+PD1 inhibitor Part2
JAB-3068+JS001 dose expansion
JAB-3068
JAB-3068 administrated orally as a tablet.
PD1 inhibitor
JS001 administrated as an intravenous(IV) infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JAB-3068
JAB-3068 administrated orally as a tablet.
PD1 inhibitor
JS001 administrated as an intravenous(IV) infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF).
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Exclusion Criteria
* Known serious allergy to experimental drugs
* Brain or spinal metastases, except if treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of progression or hemorrhage for ≤21 days before the start of treatment with the study drugs, and has not received any systemic corticosteroids for ≥21 days before the start of treatment with the study drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Jacobio Pharmaceuticals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JAB-3068-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.